

Content of N3 Bulletin, 2016

REGULATORY NEWS

- FDA APPROVES CINQAIR TO TREAT SEVERE ASTHMA
- FDA APPROVES OCALIVA FOR RARE, CHRONIC LIVER DISEASE
- FDA APPROVES VACCINE TO PREVENT CHOLERA FOR TRAVELERS
- FDA REVISES WARNINGS REGARDING USE OF THE DIABETES MEDICINE METFORMIN IN CERTAIN PATIENTS WITH REDUCED KIDNEY FUNCTION

DRUGS SAFETY

- HYDROXIZINE-CONTAINING MEDICINES
Risk of effects on heart rhythm
- VARENICLINE AND ALCOHOL
Risk of psychiatric symptoms by drug-alcohol interaction
- FLUOROQUINOLONES ORAL ANTIBIOTICS
Risk of retinal detachment
- TRIMETHOPRIM DURING THE 3 MONTHS BEFORE PREGNANCY: MALFORMATIONS IN CHILDREN
- GLIPTINS, EXENATIDE, LIRAGLUTIDE: INTESTINAL OBSTRUCTION
- AMPHETAMINE AND METHYLPHENIDATE
Risk of suicidal thoughts and behaviors
- DEFERASIROX
Risk of pancreatitis in pediatric patients

THE INTERESTING FACTS

- FIRST CASE OF COLISTINE RESISTANCE IN USA
- MULTIPLE SCLEROSIS STEM CELL THERAPY SUCCEEDS BUT POSES RISKS

EVIDENCE BASED MEDICINES

- LIRAGLUTIDE AND OBESITY
Still no satisfactory weight loss drugs
- INFLUENZA VACCINATION DURING PREGNANCY
- MIRABEGRON
Poorly effective in urge urinary incontinence
- DENOSUMAB AND MALE OSTEOPOROSIS
Do not use in men (or in women)
- RANIBIZUMAB IN HIGH MYOPIA WITH NEOVASCULARISATION
Better short-term visual acuity but serious adverse effects

PRACTICAL RECOMMENDATIONS

- BRONCHIOLITIS IN INFANTS: DO NOT USE BRONCHODILATORS
- PREVENTION OF DEEP VEIN THROMBOSIS
First choice treatments